Compare Match Group Inc (MTCH) vs Organon & Co. Common Stock (OGN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Match Group Inc vs Organon & Co. Common Stock — how do they compare? Match Group Inc trades at $42.39 (market cap $9.72B), while Organon & Co. Common Stock trades at $13.58 (market cap $3.62B). The key difference: Match Group Inc is far larger — about 2.7× Organon & Co. Common Stock's market cap, and Match Group Inc pays the higher dividend (1.89%). Which is the better fit depends on your goals — on Pluang, investors hold Match Group Inc for 115 Days and Organon & Co. Common Stock for 0 Days on average.
| MTCH | OGN | |
|---|---|---|
Market Cap | $9.72B | $3.62B |
Volume | 4,140,020 | 2,892,999 |
Sector | Media | Health |
52-Week High | $44.40 | $13.81 |
52-Week Low | $28.90 | $5.70 |
Typical Hold Time | 115 Days | 0 Days |
Enterprise Value | $12.69B | $11.04B |
Dividend Yield | 1.89% | 0.58% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
MTCH trades at $42.40, up 2.12% today, with a bullish technical signal and strong support at $41. The company reported a net income margin of 20.17% for 2025, with Q2 2026 EPS beating expectations. Operating cash flow reached $1.08B in 2025, and a $0.20 dividend is scheduled for October 2026. Recent news highlights product innovation at Tinder and growth at Hinge.
The outlook is positive with a consensus price target of $42.29, though high debt levels and competitive pressures pose risks. Analyst sentiment is bullish with 53% buy ratings. Revenue stability and margin expansion support upside potential, but investors should monitor execution on Tinder's turnaround and debt management.
Organon (OGN) trades at $13.77, showing no change in the latest session. The stock demonstrates strong profitability with 52.68% gross margins and 24.04% ROE, though recent quarterly earnings have missed expectations. Valuation appears reasonable with P/E of 17.65 and P/S of 0.59. The company shows positive cash flow trends with 2026 projections indicating $533M net cash flow. Recent FDA developments for MIUDELLA and VTAMA products highlight ongoing pipeline progress.
OGN presents a mixed outlook with solid fundamentals offset by earnings misses. The healthcare company's improving cash flow and product pipeline offer potential upside, but investor sentiment remains divided with analysts showing cautious optimism. Key risks include execution challenges and competitive pressures in the pharmaceutical sector.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Match Group Inc
Match Group is a provider of online dating products. The firm became public in 2015 and was more than 80% owned by IAC/InterActiveCorp until IAC spun it off in the second quarter of 2020. The company has a vast portfolio of different online dating service providers, including Tinder, Match.com, OkCupid, Plenty of Fish, and Meetic. Match Group has more than 45 brands of online dating sites and/or apps, from which it generates user fee revenue (95%) and advertising revenue (5%).
Read more on MTCH →About Organon & Co. Common Stock
Organon & Co. is a global healthcare company focused on women's health, biosimilars, and established brands, spun off from Merck & Co. in 2021. Its portfolio of more than 70 medicines includes contraception and fertility therapies, immunology and oncology biosimilars, and treatments in cardiovascular, respiratory, and dermatology, distributed in over 140 countries.
Read more on OGN →
